JP2022532430A5 - - Google Patents

Info

Publication number
JP2022532430A5
JP2022532430A5 JP2021568608A JP2021568608A JP2022532430A5 JP 2022532430 A5 JP2022532430 A5 JP 2022532430A5 JP 2021568608 A JP2021568608 A JP 2021568608A JP 2021568608 A JP2021568608 A JP 2021568608A JP 2022532430 A5 JP2022532430 A5 JP 2022532430A5
Authority
JP
Japan
Prior art keywords
chimeric protein
domain
cancer
ligand
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532430A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/033169 external-priority patent/WO2020232365A1/en
Publication of JP2022532430A publication Critical patent/JP2022532430A/ja
Publication of JP2022532430A5 publication Critical patent/JP2022532430A5/ja
Pending legal-status Critical Current

Links

JP2021568608A 2019-05-16 2020-05-15 Nk細胞指向性キメラタンパク質 Pending JP2022532430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848915P 2019-05-16 2019-05-16
US62/848,915 2019-05-16
PCT/US2020/033169 WO2020232365A1 (en) 2019-05-16 2020-05-15 Nk cell-directed chimeric proteins

Publications (2)

Publication Number Publication Date
JP2022532430A JP2022532430A (ja) 2022-07-14
JP2022532430A5 true JP2022532430A5 (cg-RX-API-DMAC7.html) 2023-05-23

Family

ID=73289381

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021568608A Pending JP2022532430A (ja) 2019-05-16 2020-05-15 Nk細胞指向性キメラタンパク質

Country Status (7)

Country Link
US (2) US20200399344A1 (cg-RX-API-DMAC7.html)
EP (1) EP3969058A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022532430A (cg-RX-API-DMAC7.html)
CN (1) CN114126663A (cg-RX-API-DMAC7.html)
AU (1) AU2020276296A1 (cg-RX-API-DMAC7.html)
CA (1) CA3140055A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020232365A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119039440A (zh) * 2021-07-02 2024-11-29 来凯医药科技(上海)有限公司 活化的肝星状细胞(hsc)的消耗及其用途
CN114853905B (zh) * 2022-04-14 2022-11-22 呈诺再生医学科技(珠海横琴新区)有限公司 一种基因修饰nk细胞与抗体联合使用治疗肿瘤方案
WO2024073513A2 (en) * 2022-09-27 2024-04-04 Affini-T Therapeutics, Inc. Chimeric receptors comprising interleukin 7 receptor (il7r) domains
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932055B2 (en) * 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
US20140370012A1 (en) * 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
SG10201913573UA (en) * 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
US10906957B2 (en) * 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins

Similar Documents

Publication Publication Date Title
AU2021202413B2 (en) Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
CN109069638B (zh) 用于癌症治疗的三特异性抑制剂
CN110337449B (zh) 抗pd-l1抗体及其应用
CA3141626A1 (en) Novel il-15 prodrugs and methods of use thereof
JP2023145487A (ja) 抗tim-3抗体のための投与レジメンおよびその使用
JP2019529373A5 (ja) 抗Tim−3抗体
US20220235134A1 (en) Anti-b7-h3 antibodies
JP2022512541A5 (cg-RX-API-DMAC7.html)
JP2018533371A5 (cg-RX-API-DMAC7.html)
TW202323272A (zh) 靶向flt3之嵌合抗原受體
JP2018529363A (ja) I型及びii型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法
CN113164538B (zh) 修饰的溶瘤病毒、其组合物和用途
JP2020502147A5 (cg-RX-API-DMAC7.html)
US20250019411A1 (en) T-Cell Engaging Polypeptides and Methods of Use Thereof
JP2023543896A5 (cg-RX-API-DMAC7.html)
JP7689744B2 (ja) 抗原特異的t細胞応答を活性化するための材料および方法
EP4232087A1 (en) Novel anti-lilrb2 antibodies and derivative products
JP2019536469A5 (cg-RX-API-DMAC7.html)
JP2024525758A (ja) がんのための併用療法におけるcd40およびcd137に対する多重特異性結合剤
WO2023138677A1 (en) Novel anti-lag3 antibodies and derivative products
JP2022512539A5 (cg-RX-API-DMAC7.html)
WO2022254227A1 (en) Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies
JP2023554422A (ja) がんの治療のための多重特異性抗体
US20230057939A1 (en) Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
JP2023518835A (ja) 制御性t細胞の除去用の二重特異性融合タンパク質